These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33327794)

  • 1. Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development.
    Adeghate EA; Kalász H; Al Jaberi S; Adeghate J; Tekes K
    Expert Opin Investig Drugs; 2021 Feb; 30(2):85-93. PubMed ID: 33327794
    [No Abstract]   [Full Text] [Related]  

  • 2. [Recommendations for the drug therapy of diabetes type 2. Treatment of associated vascular risk factors. French Agency for the Safety of Therapeutic Products].
    Presse Med; 1999 Oct; 28(29):1584-9. PubMed ID: 10544712
    [No Abstract]   [Full Text] [Related]  

  • 3. Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care.
    Górriz JL; Cos Claramunt FX; Duque N; Matali A
    Prim Care Diabetes; 2019 Dec; 13(6):485-494. PubMed ID: 31400992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?
    Ingelfinger JR; Rosen CJ
    N Engl J Med; 2016 Jul; 375(4):380-2. PubMed ID: 27331286
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EMPA-REG OUTCOME: The Nephrologist's Point of View.
    Wanner C
    Am J Cardiol; 2017 Jul; 120(1S):S59-S67. PubMed ID: 28606346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
    Scheen AJ; Piérard L; Krzesinski JM; Paquot N
    Rev Med Liege; 2016 Sep; 71(9):376-381. PubMed ID: 28383832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semaglutide Reduces CV Events in High-Risk Patients with Type 2 Diabetes Mellitus.
    Ebell MH
    Am Fam Physician; 2017 Mar; 95(6):396. PubMed ID: 28318215
    [No Abstract]   [Full Text] [Related]  

  • 9. Introduction.
    Dahlöf B; Ritz E
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S1-2. PubMed ID: 15868114
    [No Abstract]   [Full Text] [Related]  

  • 10. [Can glitazones provide protection of the kidneys?].
    Bonnet F
    Journ Annu Diabetol Hotel Dieu; 2007; ():77-84. PubMed ID: 18610759
    [No Abstract]   [Full Text] [Related]  

  • 11. Diabetes: Risks of strict glycaemic control in diabetic nephropathy.
    de Borst MH; Navis G
    Nat Rev Nephrol; 2015 Jan; 11(1):5-6. PubMed ID: 25366044
    [No Abstract]   [Full Text] [Related]  

  • 12. The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.
    Lioudaki E; Androulakis ES; Whyte M; Stylianou KG; Daphnis EK; Ganotakis ES
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):215-225. PubMed ID: 28444472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New drugs for type 2 diabetes: expanding cardiovascular protection beyond type 2 diabetes?].
    Mannucci E
    G Ital Cardiol (Rome); 2012 Dec; 13(12 Suppl 1):3S. PubMed ID: 23258122
    [No Abstract]   [Full Text] [Related]  

  • 15. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
    Solini A; Penno G; Bonora E; Fondelli C; Orsi E; Trevisan R; Vedovato M; Cavalot F; Cignarelli M; Morano S; Ferrannini E; Pugliese G;
    J Am Geriatr Soc; 2013 Aug; 61(8):1253-61. PubMed ID: 23889588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
    Mosenzon O; Raz I; Scirica BM; Hirshberg B; Stahre CI; Steg PG; Davidson J; Ohman P; Price DL; Frederich B; Udell JA; Braunwald E; Bhatt DL
    Diabetes Metab Res Rev; 2013 Jul; 29(5):417-26. PubMed ID: 23564755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.
    Hocher B; Tsuprykov O
    Nat Rev Nephrol; 2017 Dec; 13(12):728-730. PubMed ID: 28989173
    [No Abstract]   [Full Text] [Related]  

  • 19. Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk.
    Bailey CJ
    Lancet Diabetes Endocrinol; 2020 Feb; 8(2):97-99. PubMed ID: 31843565
    [No Abstract]   [Full Text] [Related]  

  • 20. Intensive glucose control in type 2 diabetes.
    Parashar A
    N Engl J Med; 2008 Oct; 359(14):1520; author reply 1520-1. PubMed ID: 18837128
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.